PATENT CLAIM ANALYSIS

Application Number: 16148028
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-08
Patent Classification: ["514", "289000"]

Abstract:
This disclosure provides pharmaceutical compositions comprising dextromethorphan in combination with quinidine, and methods for treating agitation and/or aggression in subjects with dementia by administering such compositions.

Claim (Index 6):
The method according to  claim 1 , wherein at least one of the quinidine and the dextromethorphan is in the form of a pharmaceutically acceptable salt chosen from salts of alkalai metals, salts of lithium, salts of sodium, salts of potassium, salts of alkaline earth metals, salts of calcium, salts of magnesium, salts of lysine, salts of N,N\u2032dibenzylethylenediamine, salts of chloroprocaine, salts of choline, salts of diethanolamine, salts of ethylenediamine, salts of meglumine, salts of procaine, salts of tris, salts of free acids, salts of free bases, inorganic salts, salts of sulfate, salts of hydrochloride, and salts of hydrobromide.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 97.0
- Lexical Diversity: 1.12
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13415067', '11035213', '15211638', '14100597', '12080756']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7609825353447524
- 35 USC 102 Novelty (BERT): 0.5292236305401378
- Combined Prediction Score: 0.7378066448642909
- Mean Citation Score: 284.692826
- Max Citation Score: 352.63284
- Similarity Product: 298.8012935521889

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test